Last checked at 25 Apr 2022 07:00
ReNeuron Group plc
("ReNeuron" or the "Company")
Director Declaration
ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Iain Ross, Chairman, has advised the Company that further to the announcement of 17 December 2021 regarding Palla Pharma Limited ("Palla Pharma"), of which he was a Non-Executive Director, entering into voluntary administration, Palla Pharma has entered into liquidation. Iain Ross's resignation from the board of Palla Pharma was accepted on 20 April 2022.
This announcement is made in accordance with AIM Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies.
ENDS
Contacts:
ReNeuron | www.reneuron.com/investors |
Iain Ross, Chairman | Via Walbrook PR |
Catherine Isted, Chief Financial Officer |
|
|
|
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) | +44 (0)20 3100 2000
|
|
|
Allenby Capital Limited (Joint Broker) | +44 (0)20 3328 5656 |
James Reeve/George Payne (Corporate Finance) |
|
Stefano Aquilino (Sales & Corporate Broking) |
|
|
|
Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com |
Paul McManus/Alice Woodings | +44 (0)7980 541 893/+44 (0)7407 804 654 |
About ReNeuron
ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com